These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
396 related articles for article (PubMed ID: 28945937)
1. Resveratrol and inflammatory bowel disease. Shi Y; Zhou J; Jiang B; Miao M Ann N Y Acad Sci; 2017 Sep; 1403(1):38-47. PubMed ID: 28945937 [TBL] [Abstract][Full Text] [Related]
2. Curcumin as a therapeutic agent in the chemoprevention of inflammatory bowel disease. Sreedhar R; Arumugam S; Thandavarayan RA; Karuppagounder V; Watanabe K Drug Discov Today; 2016 May; 21(5):843-9. PubMed ID: 26995272 [TBL] [Abstract][Full Text] [Related]
3. Resveratrol and resveratrol nano-delivery systems in the treatment of inflammatory bowel disease. Gowd V; Kanika ; Jori C; Chaudhary AA; Rudayni HA; Rashid S; Khan R J Nutr Biochem; 2022 Nov; 109():109101. PubMed ID: 35777588 [TBL] [Abstract][Full Text] [Related]
4. [Polyphenols in the treatment of inflammatory bowel diseases]. Chojnacka K; Laskowska J Postepy Biochem; 2020 Sep; 66(3):256-262. PubMed ID: 33315320 [TBL] [Abstract][Full Text] [Related]
5. Anti-Inflammatory Effects of Resveratrol in Patients with Ulcerative Colitis: A Randomized, Double-Blind, Placebo-controlled Pilot Study. Samsami-Kor M; Daryani NE; Asl PR; Hekmatdoost A Arch Med Res; 2015 May; 46(4):280-5. PubMed ID: 26002728 [TBL] [Abstract][Full Text] [Related]
6. Resveratrol and inflammatory bowel disease: the evidence so far. Nunes S; Danesi F; Del Rio D; Silva P Nutr Res Rev; 2018 Jun; 31(1):85-97. PubMed ID: 29191255 [TBL] [Abstract][Full Text] [Related]
7. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies. Magro F; Portela F BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228 [TBL] [Abstract][Full Text] [Related]
8. Polyphenol supplementation as a complementary medicinal approach to treating inflammatory bowel disease. Biasi F; Astegiano M; Maina M; Leonarduzzi G; Poli G Curr Med Chem; 2011; 18(31):4851-65. PubMed ID: 21919842 [TBL] [Abstract][Full Text] [Related]
9. Inflammatory pathways of importance for management of inflammatory bowel disease. Pedersen J; Coskun M; Soendergaard C; Salem M; Nielsen OH World J Gastroenterol; 2014 Jan; 20(1):64-77. PubMed ID: 24415859 [TBL] [Abstract][Full Text] [Related]
10. Alternative medicines as emerging therapies for inflammatory bowel diseases. Singh UP; Singh NP; Busbee B; Guan H; Singh B; Price RL; Taub DD; Mishra MK; Nagarkatti M; Nagarkatti PS Int Rev Immunol; 2012 Feb; 31(1):66-84. PubMed ID: 22251008 [TBL] [Abstract][Full Text] [Related]
11. Exploring the Impact of Cyanidin-3-Glucoside on Inflammatory Bowel Diseases: Investigating New Mechanisms for Emerging Interventions. Frountzas M; Karanikki E; Toutouza O; Sotirakis D; Schizas D; Theofilis P; Tousoulis D; Toutouzas KG Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298350 [TBL] [Abstract][Full Text] [Related]
12. Saffron as a Promising Therapy for Inflammatory Bowel Disease. Rashid M; Rashid R; Saroya S; Deverapalli M; Brim H; Ashktorab H Nutrients; 2024 Jul; 16(14):. PubMed ID: 39064796 [TBL] [Abstract][Full Text] [Related]
14. The implications of oxidative stress and antioxidant therapies in Inflammatory Bowel Disease: Clinical aspects and animal models. Balmus IM; Ciobica A; Trifan A; Stanciu C Saudi J Gastroenterol; 2016; 22(1):3-17. PubMed ID: 26831601 [TBL] [Abstract][Full Text] [Related]
15. Vitamin D as a novel therapy in inflammatory bowel disease: new hope or false dawn? O'Sullivan M Proc Nutr Soc; 2015 Feb; 74(1):5-12. PubMed ID: 25490986 [TBL] [Abstract][Full Text] [Related]
16. Hydradenitis suppurativa and inflammatory bowel disease: An unusual, but existing association. Principi M; Cassano N; Contaldo A; Iannone A; Losurdo G; Barone M; Mastrolonardo M; Vena GA; Ierardi E; Di Leo A World J Gastroenterol; 2016 May; 22(20):4802-11. PubMed ID: 27239107 [TBL] [Abstract][Full Text] [Related]
17. Hou M; Leng Y; Shi Y; Tan Z; Min X Am J Chin Med; 2023; 51(6):1501-1526. PubMed ID: 37530507 [TBL] [Abstract][Full Text] [Related]
18. [Aminosalicylates and steroids in the treatment ot chronic inflammatory bowel diseases--consensus paper of the Working Group for Chronic Inflammatory Bowel Diseases of the OGGH]. Dejaco C; Haas T; Kirchgatterer A; Miehsler W; Wenzl H; Knoflach P; Petritsch W; Vogelsang H; Reinisch W; Tilg H Z Gastroenterol; 2006 Jun; 44(6):525-38; discussion 539. PubMed ID: 16773519 [TBL] [Abstract][Full Text] [Related]
19. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement. Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279 [TBL] [Abstract][Full Text] [Related]
20. Immunopathogenesis of inflammatory bowel disease and mechanisms of biological therapies. Ahluwalia B; Moraes L; Magnusson MK; Öhman L Scand J Gastroenterol; 2018 Apr; 53(4):379-389. PubMed ID: 29523023 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]